InsidersTradesSigma
Total declarations
Companies
▲ Purchases (8 ops.)
▼ Sales (2 ops.)
Insider track record
ExecutiveDisclosed buys
8
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by CONWAY ROBERT E, Director. Director active across 3 companies, notably ARCA biopharma, Inc.. Cumulatively, 11 filings have been logged. Split: 8 buys · 2 sells. Total volume traded: €762k. History available since 5 May 2021. The latest transaction was filed on 23 September 2021 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations11 total
50,000 sharesCommon StockSEC:0001626199-24-000098:0
15,000 shares@ US$10.076918.9% of flowCommon StockSEC:0001626199-21-000130:0
Ideal exit: 20 Jun 2022 (T+270)
15,000 shares@ US$10.076918.9% of flowCommon StockSEC:0001626199-21-000130
Ideal exit: 20 Jun 2022 (T+270)
15,000 shares@ US$10.076918.9% of flowCommon StockSEC:0001626199-21-000127:0
15,000 shares@ US$10.076918.9% of flowCommon StockSEC:0001626199-21-000127
10,000 shares@ US$9.796612.3% of flowCommon StockSEC:0001626199-21-000120
Ideal exit: 18 Jun 2022 (T+270)
10,000 shares@ US$9.796612.3% of flowCommon StockSEC:0001626199-21-000120:0
Ideal exit: 18 Jun 2022 (T+270)
10,000 shares@ US$3.194733.1% of flowCommon StockSEC:0001209191-21-032381:0
Ideal exit: 6 Feb 2022 (T+270)
10,000 shares@ US$3.194733.1% of flowCommon StockSEC:0001209191-21-032381
Ideal exit: 6 Feb 2022 (T+270)
10,000 sharesCommon StockSEC:0001209191-21-030629
Ideal exit: 30 Jan 2022 (T+270)
10,000 shares@ US$3.234533.7% of flowCommon StockSEC:0001209191-21-030629:0
Ideal exit: 30 Jan 2022 (T+270)
11 of 11 declarations
About CONWAY ROBERT E
Robert E. Conway is a Director of ARCA biopharma, Inc. and ALPINE IMMUNE SCIENCES, INC. He brings extensive experience in corporate governance and strategic decision-making. His role involves overseeing the company's activities and ensuring that shareholder interests are safeguarded. His contribution is essential in guiding these companies within the biopharmaceutical sector.
